Novaliq collaborates with strong partners to ensure efficient market access and success along the Novaliq’s EyeSol® Drug Development Process.

Who is Novaliq partnering with?

  • Novaliq has an European Partnership Agreement with Ursapharm, one of the leading EU ophthalmic players. In October 2015, NovaTears® entered the EU market under Ursapharm’s brand name EvoTears®. Since then, EvoTears® has been successfully launched in 8 EU countries.
  • Novaliq has a strategic Licencing Partnership Agreement with AFT Pharmaceuticals Ltd (AFT), a New Zealand-based pharmaceutical company listed in ASX and NZX, for the commercialization of NovaTears® in Australia and New Zealand.
  • Novaliq is also working with leading academic and industry partners including CROs, CMOs offering product development expertise and execution capabilities through pre-clinical IND, clinical development and regulatory in EU/US and Japan.

How can I partner with Novaliq?

Business Contact

Dr. Hartmut Voss
Chief Business Officer Novaliq GmbH

+ 49 6221 50259-0

Media Contact

Heidrun Kirsch
VP Marketing

+ 49 6221 50259-243

How can I become a clinical trial investigator?

Please contact us at